Login
$GALT
$3.02 -$0.03 (0.98%) Live

Company Executives

Officer Age In this role Joined Source
Joel Lewis Also a director
President and CEO
Title from the Form 4/A dated Jan 16, 2026
56 Not stated Not stated
Jack W. Callicutt
Chief Financial Officer
59 Since 2013
13 years
Not stated
Khurram Jamil
Chief Medical Officer
51 Since 2024
2 years
2024

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
11
serving now
Independent
0 of 1
stated in the proxy; 10 not stated
Average tenure
8.4 years
from year joined
CEO also chairs the board
No
Richard E. Uihlein
Director Age On board Independent Committees Other public boards 2025 pay Source
Richard E. Uihlein
81 2017
9 years
Not stated None stated None stated $92,260
Joel Lewis
56 2017
9 years
Not independent None stated None stated Paid as CEO
Gilbert F. Amelio, Ph.D.
83 2009
17 years
Not stated
Compensation Committee
None stated $107,760
Henry Brem, M.D.
73 2026
this year
Not stated None stated None stated Not stated
Benjamin S. Carson, Sr., M.D.
75 2023
3 years
Not stated
Nominating and Corporate Governance Committee
D.R. Horton, Inc. $92,260
Kary Eldred
52 2018
8 years
Not stated None stated None stated $99,760
Kevin D. Freeman
65 2011
15 years
Not stated
Compensation Committee
None stated $108,260
Gilbert S. Omenn, M.D., Ph.D.
85 2014
12 years
Not stated None stated None stated $102,260
Elissa J. Schwartz, Ph.D.
56 2020
6 years
Not stated
Nominating and Corporate Governance Committee
None stated $95,760
Harold H. Shlevin, Ph.D.
77 2019
7 years
Not stated None stated None stated $92,260
Richard A. Zordani
54 2020
6 years
Not stated None stated None stated $107,260

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

4 disclosed in the proxy filed Oct 13, 2026
Up to $5.0 million
2025

March 2025 supplemental line of credit letter agreement providing up to $5.0 million, with convertible promissory notes and warrants; the full amount was drawn June 30, 2025.

With the Company Open in proxy
Up to $10.0 million
2025

July 2025 supplemental line of credit letter agreement providing up to $10.0 million, with convertible promissory notes and warrants; the full amount was drawn December 31, 2025.

With the Company Open in proxy
Up to $10.0 million
2025

December 2025 supplemental line of credit letter agreement providing up to $10.0 million, with convertible promissory notes and warrants; undrawn as of June 30, 2026.

With the Company Open in proxy
$91.0 million in aggregate principal and approximately $14.8 million in aggregate accrued interest
2026

Conversion of all outstanding convertible promissory notes from prior credit facilities into 34,376,167 shares of common stock.

With the Company Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support